Other formats:
BibTeX
LaTeX
RIS
@article{1838661,
author = {Negi, Chander Kant and Babica, Pavel and Bajard ép.Esner, Lola Murielle and Dobrovolná, Julie and Tarantino, Giovanni},
article_location = {USA},
article_number = {January 2022},
doi = {http://dx.doi.org/10.1016/j.metabol.2021.154925},
keywords = {Nonalcoholic fatty liver disease (NAFLD); Nonalcoholic steatohepatitis (NASH); Drug therapy; Clinical trials; Novel targets},
language = {eng},
issn = {0026-0495},
journal = {Metabolism: Clinical and Experimental},
title = {Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease},
url = {https://www.sciencedirect.com/science/article/pii/S0026049521002250?via%3Dihub},
volume = {126},
year = {2022}
}
TY - JOUR
ID - 1838661
AU - Negi, Chander Kant - Babica, Pavel - Bajard ép.Esner, Lola Murielle - Dobrovolná, Julie - Tarantino, Giovanni
PY - 2022
TI - Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease
JF - Metabolism: Clinical and Experimental
VL - 126
IS - January 2022
SP - 1-18
EP - 1-18
PB - W. B. Saunders Company
SN - 00260495
KW - Nonalcoholic fatty liver disease (NAFLD)
KW - Nonalcoholic steatohepatitis (NASH)
KW - Drug therapy
KW - Clinical trials
KW - Novel targets
UR - https://www.sciencedirect.com/science/article/pii/S0026049521002250?via%3Dihub
N2 - Nonalcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease worldwide. With no Food and Drug Administration approved drugs, current treatment options include dietary restrictions and lifestyle modification. NAFLD is closely associated with metabolic disorders such as obesity, type 2 diabetes, and dyslipidemia. Hence, clinically various pharmacological approaches using existing drugs such as antidiabetic, anti-obesity, antioxidants, and cytoprotective agents have been considered in the management of NAFLD and nonalcoholic steatohepatitis (NASH). However, several pharmacological therapies aiming to alleviate NAFLD-NASH are currently being examined at various phases of clinical trials. Emerging data from these studies with drugs targeting diverse molecular mechanisms show promising outcomes. This review summarizes the current understanding of the pathogenic mechanisms of NAFLD and provides an insight into the pharmacological targets and emerging therapeutics with specific interventional mechanisms. In addition, we also discuss the importance and utility of new approach methodologies and regulatory perspectives for NAFLD-NASH drug development.
ER -
NEGI, Chander Kant, Pavel BABICA, Lola Murielle BAJARD ÉP.ESNER, Julie DOBROVOLNÁ and Giovanni TARANTINO. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease. \textit{Metabolism: Clinical and Experimental}. USA: W. B. Saunders Company, 2022, vol.~126, January 2022, p.~1-18. ISSN~0026-0495. Available from: https://dx.doi.org/10.1016/j.metabol.2021.154925.
|
